OOIR: Observatory of International Research

Papers

(The H4-Index of Thrombosis Research is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)	197
Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis	179
D-dimer level is associated with the severity of COVID-19	153
Anticoagulation and bleeding risk in patients with COVID-19	94
Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19	86
Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave	85
Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia	76
Pulmonary embolism in hospitalised patients with COVID-19	75
Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and meta-analysis	75
Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome	75
Mechanisms of thrombosis and cardiovascular complications in COVID-19	74
COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?	69
Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?	67
Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review	60
COVID-19 and thrombotic microangiopathies	59
In vitro hemocompatibility testing of medical devices	57
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies	55
Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients	55
Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19	53
Genetically predicted obesity and risk of deep vein thrombosis	51
D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19	50
Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study	50
Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination	48
Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management	48
Pulmonary infarction in acute pulmonary embolism	48

Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis	46
Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: A nested case-control study	44
Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study	43
Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: Report of a case	42
Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19	40
The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort	40
Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: Multi-sourced population-based health records cohort study	40
Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis	39
Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action	38
COVID-19 and thrombosis: The role of hemodynamics	38
Lemierre syndrome: Current evidence and rationale of the Bacteria-Associated Thrombosis, Thrombophlebitis and LEmierre syndrome (BATTLE) registry	37
COVID-19 versus HIT hypercoagulability	36
Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination	36
Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia	36